Autologous tumor-infiltrating lymphocyte (TIL) therapy expanded ex vivo and reinfused to mediate patient-specific, TCR-dependent antitumor cytotoxicity.
Autologous tumor-infiltrating lymphocytes expanded ex vivo are reinfused to recognize patient-specific tumor antigens via their native T-cell receptors and kill tumor cells through perforin/granzyme-mediated cytotoxicity and cytokine release, often supported by IL-2 to enhance expansion and persistence.
Autologous TILs recognize the patient-specific neoantigen peptide presented on MHC via their native TCRs and directly kill the tumor cell through perforin/granzyme release (with possible Fas–FasL and cytokine-mediated effects).
Autologous tumor-infiltrating lymphocyte (TIL) therapy expanded ex vivo and reinfused to mediate patient-specific, TCR-dependent antitumor cytotoxicity.
Autologous tumor-infiltrating lymphocytes expanded ex vivo are reinfused to recognize patient-specific tumor antigens via their native T-cell receptors and kill tumor cells through perforin/granzyme-mediated cytotoxicity and cytokine release, often supported by IL-2 to enhance expansion and persistence.
Autologous TILs recognize HPV E6 peptide presented on HLA by tumor cells via their native TCRs and induce perforin/granzyme-mediated apoptosis (with possible Fas/FasL and cytokine-mediated cytotoxicity).
Autologous tumor-infiltrating lymphocyte (TIL) therapy expanded ex vivo and reinfused to mediate patient-specific, TCR-dependent antitumor cytotoxicity.
Autologous tumor-infiltrating lymphocytes expanded ex vivo are reinfused to recognize patient-specific tumor antigens via their native T-cell receptors and kill tumor cells through perforin/granzyme-mediated cytotoxicity and cytokine release, often supported by IL-2 to enhance expansion and persistence.
TILs recognize HPV E7 peptide presented on MHC via native TCRs and directly kill tumor cells through perforin/granzyme-mediated cytolysis (with possible Fas–FasL and cytokine effects).
Autologous tumor-infiltrating lymphocyte (TIL) therapy expanded ex vivo and reinfused to mediate patient-specific, TCR-dependent antitumor cytotoxicity.
Autologous tumor-infiltrating lymphocytes expanded ex vivo are reinfused to recognize patient-specific tumor antigens via their native T-cell receptors and kill tumor cells through perforin/granzyme-mediated cytotoxicity and cytokine release, often supported by IL-2 to enhance expansion and persistence.
Autologous TILs recognize tumor-associated antigen peptides presented on MHC via native TCRs and kill target cells through perforin/granzyme-mediated cytotoxicity (with possible Fas–FasL and cytokine effects).
A human bispecific IgG antibody (anti-BCMA × anti-CD3), also known as REGN5458 and Lynozyfic, administered intravenously. It redirects T cells to kill BCMA-expressing myeloma cells by simultaneously binding BCMA on plasma cells and CD3 on T cells, forming an immune synapse and inducing cytotoxicity.
Linvoseltamab is a human bispecific IgG antibody (anti-BCMA × anti-CD3) that redirects T cells to kill BCMA-expressing myeloma cells by simultaneously binding BCMA on plasma cells and CD3 on T cells, forming an immune synapse that activates T cells and triggers perforin/granzyme-mediated cytotoxicity and cytokine release.
Bispecific anti-BCMA×anti-CD3 redirects T cells to BCMA+ cells, forming an immune synapse that activates T cells to kill via perforin/granzyme-mediated cytotoxicity.